Affymetrix, Santa Clara, Calif, and Luminex Corp, Austin, Tex, have entered into a distribution agreement under which eBioscience, a business unit of Affymetrix, will sell Luminex’s Magpix, Luminex 200, and Flexmap 3D multiplexed assay products in specified countries in the Americas, Asia, and Europe.
“We are pleased to enter into this agreement with Luminex, the leading instrument provider supporting bead-based multiplexed assays,” says Dara Grantham Wright, senior vice president and general manager of the eBioscience business unit at Affymetrix. “This agreement deepens our relationship with Luminex, and will provide our customers an integrated solution to access a best-in-class platform with an ever-expanding, high-quality assay menu.”
Affymetrix will sell the Luminex instruments together with ProcartaPlex multiplexed immunoassays and QuantiGene Plex multiplexed quantitative gene expression assays, offering complete solutions to customers working in the fields of drug discovery and development, immunooncology, and translational research. The agreement aims to strengthen continued growth and adoption of Affymetrix’s bead-based assay portfolio, while expanding the Luminex installed base of instruments.
“By enabling Affymetrix to offer both Luminex multiplexing instruments and Affymetrix assays, we can further drive accessibility to customers focused on disease-related research around the world,” says Todd Bennett, vice president for global sales and customer operations at Luminex. “We are very pleased to enter into this agreement, and to support Affymetrix in its efforts to bring flexible, high-quality solutions to laboratories working in the fields of drug discovery and development, immunooncology, and translational research.”
The distribution agreement covers the United States, Austria, Belgium, Brazil, Canada, China, France, Germany, Ireland, Luxembourg, Mexico, The Netherlands, Poland, Switzerland, and the United Kingdom. Financial terms were not disclosed.